LivaNova PLC (NASDAQ:LIVN) Receives $79.38 Consensus PT from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $79.3750.

Several research analysts have commented on LIVN shares. Needham & Company LLC raised their price objective on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Mizuho raised their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Robert W. Baird reduced their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Stifel Nicolaus set a $80.00 target price on LivaNova in a research report on Wednesday, February 25th.

LivaNova Trading Up 1.6%

Shares of NASDAQ LIVN opened at $78.38 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The business’s 50 day moving average price is $68.46 and its 200-day moving average price is $65.50. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $79.38. The company has a market cap of $4.31 billion, a price-to-earnings ratio of 40.19 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same period in the prior year, the business posted $0.88 earnings per share. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts expect that LivaNova will post 3.72 earnings per share for the current year.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of LIVN. Artisan Partners Limited Partnership boosted its position in LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after purchasing an additional 1,067,349 shares in the last quarter. Invesco Ltd. boosted its position in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after purchasing an additional 902,447 shares in the last quarter. Scopia Capital Management LP acquired a new stake in shares of LivaNova in the 2nd quarter worth $36,657,000. Finally, Millennium Management LLC boosted its position in shares of LivaNova by 22.4% in the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after purchasing an additional 544,033 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.